Cargando…
Neuroimmunomodulatory effects of transcranial laser therapy combined with intravenous tPA administration for acute cerebral ischemic injury
At present, the only FDA approved treatment for ischemic strokes is intravenous administration of tissue plasminogen activator within 4.5 hours of stroke onset. Owing to this brief window only a small percentage of patients receive tissue plasminogen activator. Transcranial laser therapy has been sh...
Autor principal: | Peplow, Philip V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590216/ https://www.ncbi.nlm.nih.gov/pubmed/26487831 http://dx.doi.org/10.4103/1673-5374.162687 |
Ejemplares similares
-
Blood microRNAs as potential diagnostic and prognostic markers in cerebral ischemic injury
por: Martinez, Bridget, et al.
Publicado: (2016) -
Intravenous tPA for Acute Ischemic Stroke in Patients with COVID-19
por: Carneiro, Thiago, et al.
Publicado: (2020) -
Growth factor- and cytokine-stimulated endothelial progenitor cells in post-ischemic cerebral neovascularization
por: Peplow, Philip V.
Publicado: (2014) -
Neuroimmunomodulatory properties of polysialic acid
por: Gretenkort, Lina, et al.
Publicado: (2023) -
Hemi Orolingual Angioedema after tPA Administration for Acute Ischemic Stroke
por: Madden, Bryan, et al.
Publicado: (2015)